Skip to main content

Table 2 Primary Outcomes

From: Impact of pharmacist-conducted anticoagulation patient education and telephone follow-up on transitions of care: a randomized controlled trial

Variable Readmission Rates Including Unplanned Physician’s Clinic Visit
Pharmacist-counseled
n = 100
Standard of care
n = 100
OR (95% CI) P-value
Within 3 days
 Follow-up 1 call completed 92 91   0.621
 Patient called or had face-to-face contact with physician (unplanned contact) 14 4 0.238 (0.075–0.754) 0.010
 Patient referred to urgent care 2 0   0.369
 Patient readmitted (all-cause) 0 0   
Within 30 daysa
 Follow-up 2 call completed 100 97   0.246
 Patient had face-to-face contact with physician 13 11 0.928 (0.484–2.453) 0.883
 Patient readmitted (all-cause) 15 12 0.847 (0.380–1.886) 0.802
 Patient readmitted – related to anticoagulant use 7 7 0.684 (0.193–2.419) 0.650
 Time to hospitalization (mean in days, +/− SD) 16.9 +/−  9.8 21.7 +/− 7.1   0.197
Bleeding Outcomes
Within 3 days
 Follow-up 1 call completed 92 91   0.621
 Bleeding within 3 days 7 4 0.533 (0.151–1.888) 0.483
  Minor bleeding 1 2   0.523
  Clinically relevant non-major bleeding 5 2   0.333
  Major bleeding 1 0   0.435
Bleeding site (within 3 days)
 Nose bleed 1 2   0.693
 Gum bleed 0 1   0.593
 Blood in sputum 0 1   0.593
 Blood in stool 2 1   0.574
 Black/dark stool 1 1   0.975
 Blood in urine 2 0   0.435
 Bruises 1 0   0.435
Within 30 daysa
Follow-up 2 call completed 100 97   0.246
Bleeding within 30 days 14 17 1.161 (0.544–2.475) 0.700
 Apixaban 2 1   
 Dabigatran 1 3   
 Rivaroxaban 8 6   
 Vitamin K antagonist 3 7   
Minor bleeding 4 6 1.532 (0.419–5.603) 0.124
 Apixaban 0 1   
 Dabigatran 0 1   
 Rivaroxaban 3 3   
 Vitamin K antagonist 1 1   
Clinically relevant non-major bleeding 8 10 1.263 (0.329–4.848) 0.136
 Requiring medical intervention 4 4   0.159
 Leading to hospitalization 2 2   0.231
 Prompting a face to face evaluation 2 4   0.121
Major bleeding 2 1 0.660 (0.108–4.036) 0.115
 Intracranial bleeding 1 (Dabigatran) 0   0.132
 Transfusion of more than 2 units of PRBCs 1 (Apixaban) 1 (Rivaroxaban)   0.139
Bleeding site
 Nose bleed 3 2   0.653
 Gum bleed 1 2   0.369
 Blood in sputum 0 2   0.369
 Blood in stool 1 2   0.545
 Black/dark stool 1 2   0.708
 Blood in urine 2 1   0.291
 Blood vomitus 1 0   0.459
 Bruises 4 6   0.329
  1. a Reported rates within 30 days are all-inclusive (i.e. include rates within 3 days)
\